Non-invasive transcutaneous Supraorbital Neurostimulation (tSNS) using Cefaly® device in prevention of primary headaches

Headaches are one of the most common pain syndromes experienced by adult patients. International Classification of Headache Disorders identifies about 300 different entities. Primary headaches (migraine, tension-type headache, trigeminal autonomic cephalalgias, other primary headaches) has the common occurrence. Although effective treatment of these disorders is possible, it is inefficient or poorly tolerated in some patients. Neuromodulation methods, being element of multimodal treatment, provide an additional treatment option in pharmacotherapy-refractory patients. Both invasive and non-invasive stimulation methods are used. The non-invasive techniques is transcutaneous nerve stimulation using Cefaly® device. In this study, Cefaly® was used as prevention treatment in patients with pharmacotherapy-refractory headaches. This device is indicated for the prophylactic treatment of episodic primary headaches. A total of 91-patients (30 without and 61 with tSNS) were enrolled in the study, including 60-patients with migraine and 31-patients with other primary headaches. Ten courses of non-invasive peripheral (supraorbitral/supratrochlear) nerves stimulation were delivered to 57-patients; in the remaining 4 patients, the treatment was abandoned due to poor tolerance. Patients were observed for 30 days after stimulation treatment. Compared to the pre-treatment period, the reduction in the intensity of pain was observed in both the migraine group and patients with other types of headaches; this included the number of pain episodes being reduced by half, with simultaneous reduction in average pain intensity and duration of individual pain episodes. The subjective assessment of pain reduction was in the range of 40–47%. Based on our data we recommend tSNS as useful tool in the prophylaxis of primary headaches, including migraine

Non-invasive transcutaneous Supraorbital Neurostimulation (tSNS) using Cefaly® device in prevention of primary headaches

Headaches are one of the most common pain syndromes experienced by adult patients. International Classification of Headache Disorders identifies about 300 different entities. Primary headaches (migraine, tension-type headache, trigeminal autonomic cephalalgias, other primary headaches) has the common occurrence. Although effective treatment of these disorders is possible, it is inefficient or poorly tolerated in some patients. Neuromodulation methods, being element of multimodal treatment, provide an additional treatment option in pharmacotherapy-refractory patients. Both invasive and non-invasive stimulation methods are used. The non-invasive techniques is transcutaneous nerve stimulation using Cefaly® device. In this study, Cefaly® was used as prevention treatment in patients with pharmacotherapy-refractory headaches. This device is indicated for the prophylactic treatment of episodic primary headaches. A total of 91-patients (30 without and 61 with tSNS) were enrolled in the study, including 60-patients with migraine and 31-patients with other primary headaches. Ten courses of non-invasive peripheral (supraorbitral/supratrochlear) nerves stimulation were delivered to 57-patients; in the remaining 4 patients, the treatment was abandoned due to poor tolerance. Patients were observed for 30 days after stimulation treatment. Compared to the pre-treatment period, the reduction in the intensity of pain was observed in both the migraine group and patients with other types of headaches; this included the number of pain episodes being reduced by half, with simultaneous reduction in average pain intensity and duration of individual pain episodes. The subjective assessment of pain reduction was in the range of 40–47%. Based on our data we recommend tSNS as useful tool in the prophylaxis of primary headaches, including migraine

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts. June 4-7, 2019, Szczyrk, Polan

Neuromodulacja w bólach głowy - kliniczne zastosowanie neurostymulacji nerwów obwodowych u pacjentów z migrenowym bólem głowy.

Headaches are one of the most common disorders affected approximately 45% of the general population and have a considerable socioeconomic impact. It is known and described about two hundreds of different headaches. Most of them has rare occurrence and they are not life-threatening. Severe chronic headaches, where patients experience daily or almost-daily headache attacks, are highly disabling and have been estimated to affect approximately 1.4-2.2% of the population. Although effective treatments are available for most primary headaches, a proportion of chronic headache sufferers are poor responders or intolerant to pharmacological treatments. Neurostimulation techniques have increased our therapeutic options, providing additional methods for the treatment of patients with drug-resistant headache. Neurostimulation techniques for treating primary headaches range from invasive deep brain stimulation to less invasive peripheral nerves stimulation, and also noninvasive transcranial stimulation methods. Peripheral nerves stimulation (occipital or supraorbital) is one of noninvasive, safe options for primary headache treatment. In our study we used this method as a prophylaxes of migraine headaches. The trans-cutaneus nerve stimulation (supraorbital, or occipital nerves) were used for migraine prophylaxis. 32 patients with diagnosed migraine (ICHD-III) headaches were included to the study, 25 patients were treated with supraorbital nerve stimulation (10 times), 7 were treated with occipital nerves stimulation (10 times). After treatment we observed during 30 days observation period decrease of the number of pain attacks compared to pre-treatment period. The average intensity of pain and pain duration also decreased compared to pre-treatment period. The patients assessed pain relief at 50%.Bóle głowy są jedną z częściej występujących dolegliwości, mogą dotyczyć blisko 45% populacji i mają istotny wpływ społeczno-ekonomiczny. Znanych i opisanych jest około dwieście różnych zespołów bólowych głowy. Większość z nich występuje rzadko i nie stanowi zagrożenia życia. Ocenia się, że silne bóle głowy, kiedy pacjent codziennie, lub prawie codziennie odczuwa ból głowy ograniczający jego sprawność mogą dotyczyć około 1,4-2,2% populacji. Chociaż skuteczne leczenie jest możliwe w przypadku pierwotnych bólów głowy, to jednak pewna część pacjentów nie odpowiada, lub nie toleruje zaproponowanego leczenia farmakologicznego. Techniki neurostymulacyjne zwiększają możliwości terapeutyczne stając się dodatkową metodą leczenia u pacjentów opornych na leczenie farmakologiczne. Techniki neurostymulacyjne wykorzystywane w leczeniu pierwotnych bólów głowy obejmują różne metody: od głębokiej stymulacji mózgu poprzez stymulację nerwów obwodowych aż do metod nieinwazyjnych stymulacji przezczaszkowej. Stymulacja nerwów obwodowych (nerwów potylicznych, nadoczodołowych) jest jedną z nieinwazyjnych, bezpiecznych metod leczenia pierwotnych bólów głowy. W prezentowanym badaniu zastosowano tą metodę, jako metodę profilaktyczną w leczeniu migrenowego bólu głowy. Przezskórna elektrostymulacja nerwów nadoczodołowych, lub potylicznych została zastosowana u pacjentów z migrenowym bólem głowy. Do badania włączono 32 pacjentów ze zdiagnozowanym migrenowym bólem głowy (ICHD-III), u 25 pacjentów wykonywano stymulacje nerwów nadoczodołowych (10 zabiegów), u 7 pacjentów wykonywano stymulację nerwów potylicznych (10 zabiegów). Po zastosowanym leczeniu w ciągu 30 dni prowadzonej obserwacji zostało odnotowane zmniejszenie liczby napadów bólu w porównaniu z okresem przed leczeniem. Średnie natężenie bólu i czas trwania poszczególnych napadów także zmniejszyły się w porównaniu z okresem przed zabiegiem. Pacjenci ocenili ulgę w dolegliwościach na 50%

Antimycobacterial Activity of <i>Sida hermaphrodita</i> (L.) Rusby (Malvaceae) Seed Extract

The current prevalence of such lifestyle diseases as mycobacteriosis and tuberculosis is a result of the growing resistance of microorganisms to the available antibiotics and their significant toxicity. Therefore, plants can successfully become a source of new therapeutic agents. The aim of this study was to investigate the effect of protein extract from Sida hermaphrodita seeds on the morphology, structure, and viability of Mycobacterium smegmatis and to carry out proteomic characterization of the protein extract. The analyses were carried out using fluorescence and transmission microscopy, atomic force microscopy, and spectroscopy. The proteomic studies were performed using liquid chromatography coupled to tandem mass spectrometry. The studies showed that the seed extract applied at concentrations of 50–150 µg/mL exerted a statistically significant effect on M. smegmatis cells, that is, a reduction of the viability of the bacteria and induction of changes in the structure of the mycobacterial cell wall. Additionally, the SEM analysis confirmed that the extract did not have a cytotoxic or cytopathic effect on fibroblast cells. The proteomic analysis revealed the presence of structural, storage, and enzymatic proteins and peptides in the extract, which are typical for seeds. Proteins and peptides with antimicrobial activity identified as vicillins and lipid-transporting proteins were also determined in the protein profile of the extract